Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Brett Cucchiara et al, published in Stroke:
”Exploring advances in antithrombotic therapy for noncardioembolic ischemic stroke: The OCEANIC-STROKE trial marks a significant development with its dual-pathway inhibition approach using asundexian alongside antiplatelet therapy.
Current evidence highlights the efficacy of antiplatelet monotherapy and, in certain scenarios, the superiority of dual-antiplatelet therapy shortly after an event.
However, the emerging promise of factor XI/XIa inhibitors could revolutionize secondary stroke prevention, potentially enhancing efficacy without increasing bleeding risks.
Dive into the latest findings and what they signify for future treatment directions.”
Title: Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions
Authors: Brett Cucchiara, Jean M. Connors, Alejandro A. Rabinstein, Mukul Sharma
Read the Full Article on Stroke
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 09:23Claire Harrison: HemaSphere Introduces New Patient Editor Role
-
Sep 14, 2026, 09:13Eirini Zorba: Plasmapheresis in Focus Understanding Its Role in Patient Care
-
Sep 14, 2026, 08:55Abdulrahman Al-Mashdali։ Immune Checkpoint Inhibitor Associated HLH
-
Sep 14, 2026, 07:54Islam Sadek: SOHO2026 Highlights Advances in Hematologic Malignancies
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol – Will AI Replace Clinicians?
-
Sep 14, 2026, 07:19Ruhi Mehra: The Evolving Science of Stem Cell Enumeration
-
Sep 14, 2026, 07:05Don’t Overlook Superficial Clots – World Thrombosis Day